Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tdon1229on Nov 30, 2020 12:57am
144 Views
Post# 31998485

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval and Priority Review.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval and Priority Review.

The WHO trial and decision to stop the trial was based on treating already-hospitalized patients.  HCQ's efficacy is best when used as a prophylactic or during the first five days following exposure during incubation and prior to hospitalization, and also with zinc which prevents the rapid multiplication of the virus in the patient's cells, as well as with a suitable antibiotic to control other bacterial infection.

Nothing hard to understand or inconsistent.  If you check the premises and compare the results, the comparison is between early use of HCQ and later use of HCQ.  The results they're seeing are the same that have been seen since early in this epidemic.  

Use HCQ early to prevent the virus multiplying.  Once it gets into the cells and multiplies, it's time for a different treatment regimen.  Use other meds to treat after a patient is hospitalized.  The WHO trial results confirm this, as expected.  Politics and media have distorted the arguments to suit their own desires.

<< Previous
Bullboard Posts
Next >>